Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| HCC1500 | AZD6738 | 0.001 | 0.5491 | -0.11947 |
| HCC1500 | MK 1775 | 1.0 | -0.7372 | -0.11696 |
| HCC1500 | GSK2334470 | 1.0 | -0.2401 | -0.11686 |
| HCC1500 | MK 1775 | 0.01 | 0.2054 | -0.11641 |
| HCC1500 | Ulixertinib | 3.16227766 | 0.8042 | -0.11604 |
| HCC1500 | GSK2334470 | 1.0 | -0.8097 | -0.11511 |
| HCC1500 | RO-3306 | 0.316227766017 | -0.7266 | -0.11484 |
| HCC1500 | Senexin B | 0.316227766017 | -0.2227 | -0.11384 |
| HCC1500 | Alvocidib | 0.0316227766017 | -0.3528 | -0.11364 |
| HCC1500 | BMS-265246 | 0.001 | -0.6554 | -0.11267 |
| HCC1500 | Ulixertinib | 0.01 | -0.1590 | -0.11144 |
| HCC1500 | Senexin B | 0.316227766017 | -0.0181 | -0.11112 |
| HCC1500 | Ulixertinib | 0.316227766 | -0.5791 | -0.11097 |
| HCC1500 | SHP099 | 10.0 | -0.1206 | -0.10997 |
| HCC1500 | Ulixertinib | 1.0 | 1.3782 | -0.10767 |
| HCC1500 | BMS-265246 | 0.0316227766017 | 0.3396 | -0.10668 |
| HCC1500 | THZ1 | 0.0316227766017 | 0.0146 | -0.10600 |
| HCC1500 | Senexin B | 0.1 | -0.7194 | -0.10529 |
| HCC1500 | THZ531 | 0.000316227766017 | 0.1926 | -0.10526 |
| HCC1500 | AZD6738 | 10.0 | -0.9469 | -0.10036 |
| HCC1500 | THZ1 | 0.1 | -0.9765 | -0.09972 |
| HCC1500 | Senexin B | 3.16227766017 | -0.6189 | -0.09971 |
| HCC1500 | Senexin B | 0.0316227766017 | -0.7990 | -0.09949 |
| HCC1500 | Ribociclib | 0.316227766017 | 0.2444 | -0.09825 |
| HCC1500 | MK 1775 | 10.0 | -0.9395 | -0.09766 |